Abstract: The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nanoparticles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, processes for the preparation of such pharmaceutical dosage forms, and uses of the pharmaceutical dosage forms for medical purposes.

Abstract: The invention relates to a method for producing recombinant RNase A in E. coli. Said method is characterised in that it uses a DNA sequence, which codes for an RNase A of bovine origin and which is adapted to the codon usage in E. coli. The invention relates to nucleic acid molecules, which contain a nucleic acid sequence that has been adapted to the codon usage in E. coli and to recombinant nucleic acid molecules, which contain an nucleic acid molecule of this type and permit the expression of the recombinant RNase A in E. coli.

Abstract: This invention pertains to nucleic acid molecules encoding plant proteins that interact with nuclear matrix proteins and function as transcriptional activators. Using MFP1 and the yeast two-hybrid screen, MAF1 and NMP1 were isolated and sequenced and determined to be novel. Using MAF1 for a second yeast two-hybrid screen, four additional novel proteins have been isolated, sequenced and identified as FLIP1, FLIP2, FLIP3 and FLIP4. The proteins of the instant invention can be used to enhance the level of gene expression in plants and other eukaryotic organisms.